| Literature DB >> 27064649 |
Bastien Paré1, Lydia T Deschênes2, Roxane Pouliot3, Nicolas Dupré4, Francois Gros-Louis1.
Abstract
The proteins secreted by a particular type of cell, the secretome, play important roles in the regulation of many physiological processes via paracrine/autocrine mechanisms, and they are of increasing interest to help understanding rare diseases and to identify potential biomarkers and therapeutic targets. To facilitate ongoing research involving secreted proteins, we revisited cell culture protocols and whole secreted protein enrichment protocols. A reliable method for culturing and precipitating secreted protein from patient-derived fibroblast conditioned-medium was established. The method is based on the optimization of cell confluency and incubation time conditions. The well-established carrier-based TCA-DOC protein precipitation method was consistently found to give higher protein recovery yield. According to our results, we therefore propose that protein enrichment should be performed by TCA-DOC precipitation method after 48 h at 95% of confluence in a serum-deprived culture medium. Given the importance of secreted proteins as a source to elucidate the pathogenesis of rare diseases, especially neurological disorders, this approach may help to discover novel candidate biomarkers with potential clinical significance.Entities:
Keywords: 2D-DIGE; fibrolast-conditioned media; secreted proteins; secretome; secretomic
Year: 2016 PMID: 27064649 PMCID: PMC4814560 DOI: 10.3389/fncel.2016.00070
Source DB: PubMed Journal: Front Cell Neurosci ISSN: 1662-5102 Impact factor: 5.505
Detailed clinical information of patients and controls enrolled in this study.
| SALS 1 | Arm | M | 48 | NA | NA | Affected | No known ALS-associated mutations |
| SALS 2 | Arm | M | 62 | NA | NA | Affected | No known ALS-associated mutations |
| SALS 3 | Arm | M | 81 | NA | NA | Affected | No known ALS-associated mutations |
| FALS1 | Arm | F | 63 | 65 | NA | Clinically unaffected | |
| FALS2 | Arm | F | 47 | 49 | NA | Clinically unaffected | |
| FALS3 | Arm | F | 59 | 60 | NA | Affected | |
| NFM1 | Arm | M | 25 | 26 | NA | Affected | NA |
| NFM2 | Arm | M | 26 | 27 | NA | Affected | NA |
| NFM3 | Arm | F | 22 | 23 | NA | Affected | NA |
| CTRL 1 | Arm | F | 68 | 69 | NA | Control | NA |
| CTRL 2 | Arm | M | 23 | 39 | NA | Control | NA |
| CTRL 3 | Arm | M | 29 | 45 | NA | Control | NA |
SALS, Sporadic ALS; FALS, Familial ALS; NFM, Neurofibromatosis type 1; CTRL, Control; M, Male; F, Female; NA, not applicable or info not available.
Detailed protocol for gel and electrophoresis experiments.
| 40% acrylamide/bisacrylamide (37.5:1) (w/v) | 1 mL | 6.3 mL | ||||||||||
| 1.5M TRIS-HCl, pH 8.8 | 4.5 L | 52.5 mL | 52.5 mL | 50 mL | 100 mL | 50 mL | ||||||
| 0.5M TRIS-HCl, pH 6.8 | 2.5 mL | |||||||||||
| 10% SDS (w/v) | 0.1 mL | 0.18 mL | 2.1 mL | 2.1 mL | 4 mL | |||||||
| 10% APS | 0.05 mL | 0.09 mL | 2.1 mL | 1.05 mL | ||||||||
| TEMED | 0.015 mL | 0.009 mL | 360 μL | 60 μL | ||||||||
| Glycine | 120 g | |||||||||||
| SDS | 40 g | 20 g | 40 g | |||||||||
| TRIS | 576 g | 60.5 g | ||||||||||
| 30% acrylamide/bisacrylamide (37.5:1) (w/v) | 68 mL | 128 mL | ||||||||||
| Glycerol | 18 mL | 74 g | 378 g | |||||||||
| 1% bromophenol blue | 210 μL | 20 μL | ||||||||||
| 1M DTT | 0.1 g | |||||||||||
| Iodoacetamine | 1.12 g | |||||||||||
| Equilibration buffer | 10 mL | 25 mL | ||||||||||
| Urea | 355 g | |||||||||||
| Agarose type I-A | 0.4 g | |||||||||||
| Agarose type VII | 0.1 g | |||||||||||
| 5X running buffer | 20 mL | |||||||||||
| Apyrogenic water | 6.35 mL | 6.93 mL | to 4L | 85 mL | 14 mL | 90 mL | 296 mL | To 1L | to 4L | 80 mL |
Acrylamide/bisacrylamide (37.5:1) solution (w/v) (BioBasic Inc, Markham, Ontario, Canada), agarose type 1-A (Sigma, Oakville, Québec, Canada), ammonium persulfate (BioBasic Inc, Markham, Ontario, Canada), bromophenol blue (Sigma, Oakville, QC, Canada), dithiothreitol (DIT) (BioBasic Inc, Markham, Ontario, Canada), glycerol (BioBasic Inc, Markham, Ontario, Canada), glycine (BioBasic Inc, Markham, Ontario, Canada), iodoacetamide (BioBasic Inc, Markham, Ontario, Canada), sodium dodecyl sulfate (SDS) (BioBasic Inc, Markham, Ontario, Canada), TRIS (BioBasic Inc, Markham, Ontario, Canada), TRIS-HCI (BioBasic Inc, Markham, Ontario, Canada), tetramethylethylenediamine (TEMED) (BioBasic Inc, Markham, Ontario, Canada), urea (BioBasic Inc, Markham, Ontario, Canada), 2-hydroxythylagarose type VII (Sigma, Oakville, Quebec, Canada).
Detailed migration protocol for the 2D gel electrophoresis.
| Step 1 | 500 | 500 | 75 | 20 |
| Step 2 | 1000 | 800 | 75 | 20 |
| Step 3 | 10,000 | 16,500 | 75 | 20 |
| Step 4 | 10,000 | 32,200 | 75 | 20 |
Figure 1Protein recovery yield in function of precipitation methods, collection times, and confluence levels measured by the Bradford assay. The yield of protein recovered following the two tested protein precipitation methods (TCA-DOC and TCA-NLS-THF) and four different culture conditions was measured by the Bradford assay. The amount of recovered protein for all the tested conditions is given in μg/ml of conditioned-supernatant. The TCA-DOC method consistently gave better recovery yields independent of the induction conditions that were used. ***Corresponds to a P-value of < 0.0001.
Figure 2One dimension SDS-PAGE gel of secreted proteins precipitated from fibroblast conditioned-medium and conjugated with CyDyes. (A) Conjugation of CyDyes 3 and 5 to TCA-DOC and TCA-NLS-THF precipitated proteins. A 14% acrylamide/bisacrylamide (37.5:1) gel was used to resolve the CyDye conjugated supernatant protein. An internal standard was produced by conjugating protein from the TCA-DOC (Post-48 h) with both Cy3 (green) and Cy5 (red) dyes. One fibroblast cell line per tested condition for each of the studied pathology and control was tested and loaded in the gels in this order: pre-confluence/24 h, post-confluence/48 h, pre-confluence/48 h, post-confluence/48 h. Equal amount of proteins was loaded in all the gels. (B) Quantification of the fluorescent signal, detected with our laser-scanner Typhoon device, was done using ImageJ software. No statistical differences were noted for each of the tested condition, indicating that any of the protein precipitation method used in this study did not interfere with the CyDye conjugation.
Figure 3Visualization of whole secreted protein and quantification of the protein spots resolved with 2D-DIGE at the optimal induction condition. Conjugation of each CyDye, Cy2 (A), Cy3 (B), and Cy5 (C), to precipitated proteins extracted from fibroblast conditioned-medium via the TCA-DOC method and resolved by 2D-DIGE is shown. Please note that all technical replicates (disease and control) obtained for the 48 h post-confluence induction condition were pooled together prior CyDye conjugation and loaded on gel. (D) Represents a fusion image of the three different CyDyes. Each individual spot is circled. The number of detected spots (502) is indicated at the far right. Equal number of spots is detected for each of the tested CyDyes indicating that each of the specific tested CyDyes bond with the same effectiveness and therefore that the conjugation efficiency is independent of the CyDye fluors.
Figure 4Visualization and quantification of the protein spots of different tested induction conditions and precipitation methods. Proteins were conjugated with the different CyDyes after extraction with the TCA-DOC, 24 h, post-confluence (Cy2) (A), TCA-NLS-THF, 48 h, post-confluence (Cy3) (B) and TCA-DOC, 48 h post-confluence (Cy5) (C) induction conditions and precipitation methods and resolved by 2D-DIGE from one control cell line. Each individual spot is circled and was automatically quantified by the software (far right). Note that the TCA-DOC 48 h post-confluence induction condition, which was also consistently given better protein recovery yield, gave the highest number of protein spots.
Available 2D gel analysis software and spot quantification.
| Bio-Rad, Hercules, CA, USA | PDQuest-2D |
| DECODON, Greifswald, Germany | Delta2D |
| GE Healthcare, Little Chalfont, Buckinghamshire, United Kingdom | DeCyder 2D/Image Master 2D Platinum |
| Genbio, Geneva, Switzerland | Melanie |
| Ludesi, | Redfin |
| Syngene, Frederick, MD, USA | Dymension |
| Totallab, Newcastle upon Tyne, United Kingdom | SameSpots |